Research library

Individual studies, conference abstracts, patents and trial registrations. Each record identifies the study population or model, results and original source.

Filter studies

Findings from selected studies

  • Peptide persistence in mouse plasma

    Radiolabeled HAEEPGP had approximately twice the plasma half-life of radiolabeled HAEE in mice. The comparison measured persistence in circulation.

1142 of 1142 records · Showing 30

2021 · Randomized trial · Full text available

Oral Epitalon for prolonged stress and Vilon during recovery from infection: two placebo comparisons ↗

Epitalon · Vilon

After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.

Who or what was studied: Epimental: 560 adults aged 35–68 after prolonged occupational or emotional stress, including time-zone changes (270 active, 290 placebo). Regevil: 520 adults aged 43–76 recovering from acute respiratory, bacterial or viral illness (276 active, 244 placebo).

Read results, methods & source →

2024 · Human comparative study · Full text available

Retinalamin in diabetic retinopathy: three-month imaging and electrical responses ↗

Retinalamin

At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.

Who or what was studied: 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).

Read results, methods & source →

2026 · Randomized trial · Russian-language source

Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration ↗

Retinalamin

At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).

Who or what was studied: 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).

Read results, methods & source →

2018 · Uncontrolled human report · Full text available

Prostatilen AC: three-month sperm DNA fragmentation follow-up ↗

Prostatilen

Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.

Who or what was studied: 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.

Read results, methods & source →

2022 · Randomized trial · Full text available

Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation ↗

Prostatilen

Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.

Who or what was studied: 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.

Read results, methods & source →

2023 · Randomized trial · Full text available

Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility ↗

Prostatilen

At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).

Who or what was studied: 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).

Read results, methods & source →

2013 · Uncontrolled human report · English abstract

Pancragen Forte: four weeks in 12 older adults with impaired glucose tolerance ↗

Pancragen

After four weeks of Pancragen Forte at 500 µg twice daily, the authors reported lower glucose during a tolerance test in half of the 12 treated adults. The abstract leaves the size of the change and the response threshold unspecified.

Who or what was studied: 12 older adults with impaired glucose tolerance received treatment. The screening sample included 150 people across three age groups, of whom 69 were 60 or older.

Read results, methods & source →

2007 · Animal / experimental · English abstract

Pancragen in diabetic rats: blood glucose and mesenteric capillary outcomes ↗

Pancragen

The authors reported lower blood glucose during oral treatment and normalization of endothelial adhesion measures after intramuscular treatment. Capillary permeability was unchanged with intramuscular treatment.

Who or what was studied: Wistar rats with streptozotocin-induced diabetes. The abstract leaves arm sizes, doses and observation time unspecified.

Read results, methods & source →

2015 · Uncontrolled human report · Full text available

Retinalamin in retinal dystrophy: a 46-patient long-term comparison ↗

Retinalamin

Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.

Who or what was studied: 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.

Read results, methods & source →

2021 · Human comparative study · Full text available

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration ↗

Retinalamin · Cortexin · Ventfort

Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Who or what was studied: 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.

Read results, methods & source →

2008 · Animal / experimental · Full text available

Pancragen in irradiated older rats: pancreatic proliferation markers ↗

Pancragen · KED

Pancreatic PCNA-positive density was 8,176 per mm² with Pancragen and 6,524 per mm² with irradiation alone. T-38 was tested in a separate arm and had a density of 7,812 per mm².

Who or what was studied: 50 male Wistar rats, five groups of ten: young intact, aged intact, aged irradiated, aged irradiated plus T-38, and aged irradiated plus Pancragen.

Read results, methods & source →

2013 · Human comparative study · Russian-language source

Suprefort with and without Cerluten and Endoluten in type 2 diabetes ↗

Suprefort · Cerluten · Endoluten

The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.

Who or what was studied: 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.

Read results, methods & source →

2013 · Human comparative study · Russian-language source

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis ↗

Ventfort · Cerluten · Svetinorm · Endoluten

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Who or what was studied: 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Read results, methods & source →

2013 · Randomized trial · Russian-language source

Normophthal added to Retinalamin for early age-related macular degeneration ↗

Normophthal · Retinalamin

After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.

Who or what was studied: 120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.

Read results, methods & source →

2019 · Human comparative study · Russian-language source

Zhenoluten and Endoluten in women with reduced reproductive function ↗

Zhenoluten · Endoluten

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Who or what was studied: 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.

Read results, methods & source →

2017 · Human comparative study · English abstract

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis ↗

Tireogen · Endoluten

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Who or what was studied: 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.

Read results, methods & source →

2007 · Animal / experimental · English abstract

Pancragen and pancreatic cell markers in streptozotocin-treated rats ↗

Pancragen

Insulin-positive pancreatic cell area was 6.43% with injected Pancragen, 5.53% with oral Pancragen and 2.42% with streptozotocin alone. Insulin staining intensity was similar across groups.

Who or what was studied: 28 male Wistar rats, four groups of seven: intact, streptozotocin only, streptozotocin with intramuscular Pancragen, and streptozotocin with oral Pancragen.

Read results, methods & source →

2023 · Human comparative study · Full text available

Trekrezan in adults and adolescents with acute respiratory viral infections ↗

Trekrezan

Adolescent fever lasted 2.5 days less with Trekrezan. At days 3–5, fatigue persisted in 47.3% of treated adults and 70% of adult controls drawn from the earlier study.

Who or what was studied: 172 outpatients. Trekrezan plus symptomatic care: 75 adults and 47 adolescents. Symptomatic care: 30 adults and 20 adolescents. All 30 adult controls came from the 2021 Frolova study.

Read results, methods & source →

2022 · Human comparative study · Full text available

Trekrezan in 103 inpatients with ongoing symptoms after COVID-19 ↗

Trekrezan

Mean MFI-20 fatigue scores fell from 44.5 to 31.9 with add-on Trekrezan and from 41.2 to 36.7 in the comparison group. Hospital stays averaged 11.4 vs 12.5 days.

Who or what was studied: 103 hospital inpatients with ongoing symptoms after moderate or severe COVID-19. Background care plus Trekrezan: 53. Background care without adaptogens: 50.

Read results, methods & source →

2017 · Human comparative study · Full text available

Dose-ranging cognitive report from the 25-patient Dilept pilot ↗

Dilept

The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.

Who or what was studied: 25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.

Read results, methods & source →

Educational information, not medical advice. Seek qualified healthcare help for medical conditions. Source access describes the linked material; it does not imply that every method has been appraised.

Recent research updates · Tissue-preparation reports